Rho kinase inhibitor Y-27632 shows promise in Airway hyperresponsiveness

Mitsubishi Tanabe’s Rho kinase inhibitor Y-27632 has been shown to reduce the immediate allergen-induced peak rise in pleural pressure and protect against airway hyperresponsiveness

Wistar Institutes organometallic PI3K inhibitor

Researchers from the Wistar Institute describe the design of a novel organometallic PI3K inhibitor E5E2, with mid-low nanomolar potency

Ariad release Phase I data on mTOR Inhibitor deforolimus

Phase 1 data on deforolimus showed the drug was well tolerated and had predictable pharmacokinetics. The clinical benefit of the oral formulation were comparable to previously tested IV formulations. Detailed data will be presented at ASCO.

Genentech clinical updates (full data to be presented at ASCO)

Multiple updates on Avastin clinical progress to be presented as ASCO
Updates on HER 2 program (Herceptin, Pertuzumab, Trastuzumab-DM1)

Tykerb plus Herceptin increase PFS

Results from a Phase III trial show that the administration of Tykerb in combination with Herceptin increases progression free survival in HER2 positive breast cancer

Erbitux imnproves Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer

Data from a Phase II trial of Erbitux given in combination with Folfox shows the drug to significantly improves both response rate and progression-free survival over Folfox alone in the first-line treatment of metastatic colorectal cancer.

Nexavar improves survival in liver cancer by 47percent

Nexavar (sorafenib) has been shown to significantly improve overall survival by 47.3% in a phase III trial in patients with either advanced hepatocellular carcinoma or primary liver cancer